Internal Medicine, Pulmonary Disease · Philadelphia, PA
NPI
1417998956
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
834 Walnut St, Suite 650
Philadelphia, PA, 19107
Phone (215) 955-5161
Groups this clinician bills Medicare through
Medicare paid, 2024
$49K
1,505 services
Medicare patients, 2024
538
Average age 73
Drug cost, 2024
$9.6M
1,731 prescriptions
Company payments, 2025
$116
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Scharf was code 94729 (pulmonary function testing), 284 times for 278 patients. In total Michael Scharf billed 1,505 services in 41 codes, and Medicare paid $49K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-10-10.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 94729 Pulmonary Function Testing | Facility | 284 | 278 | $6.79 | $1,929 |
| 94726 Pulmonary Function Testing | Facility | 262 | 256 | $9.10 | $2,385 |
| 94010 Pulmonary Function Testing | Facility | 178 | 172 | $6.23 | $1,109 |
| 94060 Pulmonary Function Testing | Facility | 138 | 137 | $7.71 | $1,064 |
| 99214 Office E&M - Established | Facility | 126 | 93 | $72.95 | $9,191 |
| 99232 Hospital E&M - Subsequent | Facility | 98 | 52 | $62.64 | $6,139 |
| 99233 Hospital E&M - Subsequent | Facility | 79 | 37 | $95.22 | $7,523 |
| 94618 Pulmonary Function Testing | Facility | 48 | 46 | $15.91 | $764 |
| 99213 Office E&M - Established | Facility | 36 | 34 | $50.24 | $1,809 |
| 99204 Office E&M - New | Facility | 28 | 28 | $96.45 | $2,700 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 26 | 24 | $12.74 | $331 |
| 99222 Hospital E&M - Initial | Facility | 26 | 26 | $105.27 | $2,737 |
| 99214 Office E&M - Established | Office | 15 | 12 | $77.80 | $1,167 |
| 99215 Office E&M - Established | Facility | 14 | 13 | $91.38 | $1,279 |
| 99238 Hospital Discharge Management | Facility | 13 | 12 | $63.43 | $825 |
By year: 2022 $64K for 1,653 services; 2023 $57K for 1,483 services; 2024 $49K for 1,505 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael Scharf prescribed most often to Medicare patients was Tadalafil, with 193 prescriptions and refills. In total Michael Scharf wrote 1,731 Medicare prescriptions that cost $9.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tadalafil Generic | 193 | 223 | 28 | $164K |
| Opsumit Macitentan | 181 | 187 | 24 | $2.3M |
| Ambrisentan Generic | 113 | 115 | 16 | $543K |
| Tyvaso Dpi Treprostinil | 104 | 104 | 11 | $2.5M |
| Albuterol Sulfate Hfa Albuterol Sulfate | 102 | 116 | 30 | $3,173 |
| Uptravi Selexipag | 100 | 106 | 12 | $2.3M |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 85 | 99 | 19 | $62K |
| Prednisone Generic | 77 | 101 | 11 | $413 |
| Breo Ellipta Fluticasone/Vilanterol | 75 | 81 | 15 | $31K |
| Sildenafil Citrate Generic | 59 | 107 | 13 | $25K |
| Spironolactone Generic | 53 | 77 | Under 11 | $406 |
| Montelukast Sodium Generic | 49 | 91 | 12 | $377 |
| Adempas Riociguat | 42 | 46 | Under 11 | $650K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 41 | 53 | 15 | $6,293 |
| Incruse Ellipta Umeclidinium Bromide | 33 | 43 | Under 11 | $14K |
Brand drugs: 971 claims; generic drugs: 760 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Scharf $116 ($116 in general payments such as food, travel and fees) from 4 companies. The largest payer was Merck Sharp & Dohme LLC with $77.1.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.